Alpha therapy a ‘viable option’ for metastatic castration-resistant prostate cancer
No serious side effects or treatment-related deaths were reported.
Targeted alpha therapy is safe and effective for treating metastatic castration-resistant prostate cancer when other anticancer agents have failed, show results from the largest trial to date.
International researchers say actinium-225 prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) has a “substantial antitumour effect”, with most treated patients experiencing a decline in prostate specific antigen (PSA) levels.
